Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth

Core Insights - Royalty Pharma plc (NASDAQ:RPRX) is recognized as one of the best pharmaceutical stocks to buy according to billionaires, driven by strategic financial moves and growth in biopharma royalties [1][2] Financial Moves - The company completed a $2 billion senior notes offering maturing in 2031, 2035, and 2055, which enhances its capacity to acquire long-duration royalty assets and strengthen its capital structure [1][4] - Q2 2025 portfolio receipts increased by 20% year-over-year, with a target of $4.7 billion in receipts by 2030 [2] Growth and Strategy - Royalty Pharma has tripled its headcount since its 2020 IPO and invested in data analytics while streamlining operations [2] - The company is focusing on innovation, particularly in oncology, with a $2 billion funding deal with Revolution Medicines for synthetic royalties on daraxonrasib [3] Market Position - Analysts remain optimistic about Royalty Pharma, with TD Cowen reaffirming a buy rating and a price target of $42, indicating strong performance and promising future growth [4]